Tetsuya Tajima, Koichiro Hata, Jiro Kusakabe, Hidetaka Miyauchi, Kimiko Yurugi, Rie Hishida, Eri Ogawa, Tatsuya Okamoto, Mari Sonoda, Shoichi Kageyama, Xiangdong Zhao, Takashi Ito, Satoru Seo, Hideaki Okajima, Miki Nagao, Hironori Haga, Shinji Uemoto, Etsuro Hatano – 22 May 2022 – Donor–recipient human leukocyte antigen (HLA) compatibility has not been considered to significantly affect liver transplantation (LT) outcomes; however, its significance in living‐donor LT (LDLT), which is mostly performed between blood relatives, remains unclear.

Yusuke Kimura, Yukinori Koyama, Kojiro Taura, Aoi Kudoh, Kanae Echizen, Daichi Nakamura, Xuefeng Li, Nguyen Hai Nam, Yusuke Uemoto, Takahiro Nishio, Gen Yamamoto, Satoru Seo, Keiko Iwaisako, Akira Watanabe, Etsuro Hatano – 22 May 2022

Junwei Zhang, Jinyu Fang, Ziyu Xun, Yiyao Xu, Xin Lu, Haitao Zhao – 22 May 2022

Rachel L. Bachrach, Shari S. Rogal – 22 May 2022

Ivo J. Schurink, Fenna E. M. Leemkolk, Constantino Fondevila, Riccardo De Carlis, Eric Savier, Gabriel C. Oniscu, Volkert A. L. Huurman, Jeroen Jonge – 22 May 2022 – Acceptance of liver grafts from donations after circulatory death (DCD) largely remains a “black box,” particularly due to the unpredictability of the agonal phase. Abdominal normothermic regional perfusion (aNRP) can reverse ischemic injury early during the procurement procedure, and it simultaneously enables graft viability testing to unravel this black box.

Andrew M. Shearer, Yanling Wang, Elizabeth K. Fletcher, Rajashree Rana, Emily S. Michael, Nga Nguyen, Manal F. Abdelmalek, Lidija Covic, Athan Kuliopulos – 22 May 2022

Henry C. Lin – 22 May 2022

Xuezhen Zeng, Guanrui Liao, Shumin Li, Haining Liu, Xiao Zhao, Shuang Li, Kai Lei, Shenghua Zhu, Zhihang Chen, Yi Zhao, Xuxin Ren, Tianhong Su, Alfred Sze‐Lok Cheng, Sui Peng, Shuibin Lin, Ji Wang, Shuling Chen, Ming Kuang – 21 May 2022

This special interest group aims to help patients with alcohol-associated liver disease through education and research that can drive advances in patient care and government and healthcare.

The mission of the Acute on Chronic Liver Failure SIG is to promote increased understanding of the changing landscape of research into patients with chronic liver disease and cirrhosis who develop acute deterioration of their condition. Through consortia and multi-center studies, the definition, prognostication and therapeutic strategies of acute-on-chronic liver failure are explored.

The overall goal is to generate interest and encourage continuing research into this fast-increasing condition.